http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-507792-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7131b8013a60d371a5889f4dfb7a9f5b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 1999-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dae5bb005a349e623186ecd33a75a1d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_835ee83f1e13543efe3a6fe1e8ca6498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc4951a264903cb978145813a0e2f6a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb6e3bc9ffe3c8b35b69af74c5d41c76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_171a6058ce8f3972efbb221fe84b1483 |
| publicationDate | 2003-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-507792-A |
| titleOfInvention | Melanocortin 1 receptor selective compounds |
| abstract | The compound of formula (1) is described wherein: R1, R2, R2a, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each selected from H and methyl; R13, R14, R15 and R16 are selected from H and an alkyl group selected from methyl, ethyl, propyl, isopropyl, or wherein optionally one hydrogen in R13 and one hydrogen in R14 is exchanged for a bond between R13 and R14, or wherein optionally one hydrogen in R15 and one hydrogen in R16 is exchanged for a bond between R15 and R16, and wherein L1 and L2 are linker groups which are independently selected from the group consisting of single bond, methyl, ethyl; R19, R20 and R21 are selected from H and -CH2X, where X is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, heteroalkenyl, substituted heteroalkenyl, alkynyl, substituted alkynyl, heteroalkynyl, substituted heteroalkynyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, functional group; NT is selected from H, hydroxyl, alkyl, amino acid analogue, polypeptide and functional group, and CT is selected from hydrogen, hydroxyl, alkyl, amino acid, amino acid analogue, polypeptide and functional group, and wherein each asymmetric center (*) is in R or S configuration; moiety A and moiety B are optionally exchanged for H, Hydroxyl, alkyl, amino acid, amino acid analogue, polypeptide of functional group; and optionally moiety D and moiety E are exchanged for amino acid or amino acid analogue The compound is capable of inhibiting NO(nitric oxide) production or the formation of nitrite, and is capable of decreasing the formation of interleukin 1 (IL-1), interleukin 6 (IL-6), and/or tumour necrosis factor a (TNF- a), to decrease production of nitric oxide and/or to down- regulate the activity of nitric oxide synthase (NOS), and is capable of stimulating the production of interleukin 8 (IL-8) and/or interleukin 10(IL-10). The compound can be used in the manufacture of a medicament for immunomodulation, for contact hypersensitivity, sensitization by a hapten, for affecting the induction of hapten tolerance, oedema, inflammation of blood vessels or vasculitis, for normalization of white blood cell counts, for stimulation of cAMP, allergy, hypersensitivity, bacterial infection, viral infection, inflammation caused by toxic agent, fever, autoimmune disease, radiation damage by any source including UV-radiation, X-ray radiation, g- radiation, a- or b-particles, sun bums, elevated temperature, mechanical injury and hypoxia, for inflammatory diseases of the skin, in the abdomen, of the eye and tear glands, ear, nose , mouth, heart, liver, pancreas, kidney and joints, and for stimulating pigment formation in epidermal cells, such as skin tanning for cosmetic reasons, or any other condition where darkening of skin colour is desired. |
| priorityDate | 1998-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 588.